Tactile Systems Technology Inc is a medical technology company... Show more
Tactile Systems Technology, Inc., which operates as Tactile Medical, is a developer of at-home therapies for chronic vascular and lymphatic conditions. Its third quarter 2026 report offers investors a window into whether the company's dominant lymphedema franchise can keep compounding while a smaller airway clearance line works through a distribution reset. The quarter also tests whether management's aggressive spending on its sales organization and technology translates into profit, or merely offsets gross margin gains. With shares having run up significantly after earlier 2025 reports, this print carried heightened expectations around execution, cost discipline, and the durability of double-digit lymphedema growth.
Total revenue for the quarter ended September 30, 2026, increased 7% year over year to $91.9 million, just below the consensus estimate of roughly $91.99 million. Lymphedema revenue, which includes the Flexitouch, Nimble, and LymphaTech product lines, climbed 13% to $81.8 million, its fifth consecutive quarter of double-digit growth. In contrast, airway clearance (AffloVest) revenue declined 25% to $10.0 million, which management attributed to DME suppliers working through inventory during the second-quarter rollout of a next-generation vest.
GAAP net income fell to $7.2 million, or $0.31 per diluted share, from $8.2 million, or $0.36 per diluted share, in the prior-year period. Operating income declined to $9.6 million from $11.0 million as operating expenses rose 13% to $60.9 million. Gross margin expanded to 76.7% from 75.8%, while adjusted EBITDA was essentially flat at $14.3 million, slightly above analyst estimates.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending names, breakout candidates, and market opportunities far more efficiently than manual screening. For investors monitoring medical device earnings like Tactile Systems Technology's, it can help identify comparable setups across the sector in less time.
Shares fell roughly 8% in after-hours trading following the report, as investors weighed solid top-line growth against a profit decline driven by rising operating expenses. The divergence between the two product lines framed the market's interpretation: the core lymphedema business remains strong, but spending is currently growing about as fast as revenue, limiting the benefit to the bottom line. The raised adjusted EBITDA outlook was not enough to offset concerns that the fourth quarter may show softer year-over-year profit growth. Sentiment heading into the print had been optimistic after a strong first half, making the modest revenue miss and cost pressure a source of near-term disappointment.
Management kept its full-year 2026 revenue guidance at $360 million to $366 million, representing roughly 9% to 11% growth, while raising adjusted EBITDA guidance to $50 million to $52 million from the prior $49 million to $51 million. Investors should watch whether the airway clearance transition normalizes in the coming quarters, since management has not specified exactly when dealer inventory levels will reset.
Expense discipline is the central swing factor. Sales and marketing plus reimbursement and administrative costs both grew faster than revenue, and those investments only pay off if lymphedema growth accelerates or holds its double-digit pace. Gross margin expansion has been a reliable tailwind for 12 consecutive quarters, and continued improvement could cushion the impact of higher spending.
Other items to monitor include payer-channel trends, particularly Medicare and commercial mix, the ramp of newer products, and any further updates to capital allocation following the company's share repurchase activity. Broader reimbursement dynamics in the medical device space also remain relevant to the outlook.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a medical devices developer
Industry MedicalNursingServices